There is increasing evidence that myocardial fibrosis plays a role in the pathogenesis of diastolic dysfunction in hypertensive heart disease. However, it has been difficult to explore the mechanisms of isolated dias- 
Introduction
In one-third to one-half of patients who are diagnosed as having congestive heart failure (CHF), systolic function of the left ventricle (LV) is preserved, indicating that diastolic dysfunction is a major pathophysiological abnormality in these patients ( 1 − 3 ). Diastolic dysfunction is highly prevalent, particularly in hypertensive elderly patients ( 3 , 4 ) . Patients with diastolic dysfunction are susceptive to pulmonary congestion, because the LV end-diastolic pressure (LVEDP) increases upon mild effort or mild volume overload ( 5 ). This is the major cause of impaired quality of life in patients with diastolic dysfunction. In some patients with diastolic dysfunction, impairment of systolic function also progresses and eventually leads to death. Furthermore, recent epidemiological studies showed that the prognosis of CHF patients with normal systolic function is not always better than that in CHF patients with impaired systolic function ( 6 ) . Therefore, appropriate therapy is desirable, but there is no available therapy specific for the prevention and improvement of diastolic dysfunction at present.
The histological features of hypertensive cardiac remodeling are myocyte hypertrophy and myocardial fibrosis. These changes are basically adaptive responses to pressure overload. However, it is considered that when hypertension persists, disproportionate LV hypertrophy and myocardial fibrosis develop and in turn result in diastolic and eventually systolic dysfunction ( 7 ) . Given that recent studies have demonstrated the substantial involvement in the inflammatory process in the pathogenesis of various cardiovascular diseases, such as atherosclerosis ( 8 ) , inflammatory changes may play a role in cardiac remodeling in the hypertensive heart as well. In this review, we introduce our recent studies showing that pressure overload-induced perivascular inflammation triggers myocardial fibrosis and resultant diastolic dysfunction and that the regulation of inflammation is a possible therapeutic strategy for targeting diastolic dysfunction in hypertensive hearts.
Myocardial Remodeling in Hypertensive Hearts
Myocyte hypertrophy and myocardial fibrosis are important adaptive mechanisms in response to pressure overload onto the LV ( 9 ) . Hypertension increases wall stress of the LV. Increased wall stress is compensated by a parallel increase in the contractile units of the cardiac myocytes, leading to myo- (27) .
cyte hypertrophy and resultant LV wall thickening. And, an adequate degree of myocardial fibrosis prevents the ventricular deformation by increased tensile stress and transmits the force generated by hypertrophied myocytes to the entire ventricle. However, prolonged increase in cardiac work results in excessive myocyte hypertrophy and disproportionate myocardial fibrosis, which are responsible for increased myocardial stiffness and impaired pumping capacity in hypertensive patients (7) . In the early phase of hypertensive heart disease, fibrotic tissue is observed mainly in the perivascular space. Thereafter, fibrosis extends from the perivascular space to the interstitium surrounding the muscle fibers. This type of fibrosis is called "reactive fibrosis" (10) . And, in patients with uncontrolled, chronic hypertension, myocyte damage and myocyte loss are induced by excessive mechanical load and sustained, inadequate activations of neurohumoral factors, including catecholamines, the renin-angiotensin-aldosterone system (RAAS), and endothelin. Consequently, patchy or massive scarring occurs in the myocardium where myocyte loss is replaced by the fibrous tissue (replacement fibrosis) (10) . These changes lead to further deterioration of the LV pumping capacity.
Diastolic Dysfunction in Hypertrophic Hearts
LV diastolic dysfunction in cardiac hypertrophy results from two different mechanisms, namely, alteration in active relaxation and change in diastolic compliance (11, 12) . Ventricular relaxation is a dynamic process that occurs during isovolumetric relaxation and early ventricular filling. The rate of ventricular relaxation is controlled primarily by the calcium uptake by the sarcoplasmic reticulum (SR) and by the sequestration of calcium from the myocytes. These processes are regulated by energy-dependent, that is, adenosine triphosphate (ATP)-dependent mechanisms, i.e., sarcoplasmic reticulum calcium-adenosine triphosphatase (SERCA) and sarcolemmal calcium pumps, respectively. In hypertrophied myocytes, the energy-dependent calcium handling is impaired by the quantitative and qualitative alterations of SERCA, phospholamban (a regulatory factor of SERCA), and ryanodine receptors (calcium-releasing channel of the SR), as well as the contractile elements. And, impaired calcium handling delays active relaxation (13) . Myocardial ischemia deteriorates the active relaxation as well, because the ATP depletion causes malfunction of the ATP-dependent calcium handling process. In contrast, changes in diastolic compliance are direct consequences of exceeded chamber compliance and tissue stiffness (14) . Ventricular chamber compliance depends on the ventricular diameter, and ventricular tissue stiffness is determined by the wall thickness, myocyte hypertrophy, and myocardial fibrosis. There is growing evidence that myocardial stiffening depends mainly upon myocardial fibrosis rather than LV wall thickening and myocyte hypertrophy in spontaneously hypertensive rats (SHRs) (15, 16) , experimental renovascular hypertensive rats (17) , and Dahl salt-sensitive rats (18) . In these experimentally induced pressure-overload models and in patients with hypertension, there is an increase in the quantity of interstitial collagen, particularly fibrillar collagen (i.e., collagen type I and collagen type III), in the hearts (19) . The accumulation of fibrillar collagen increases the inherent viscoelasticity and passive stiffness of the hypertrophied myocardium (11) . Alterations of the distribution and microstructure of collagen, as well as imbalance of type I vs. type III collagens, affect myocardial stiffness and diastolic properties as well (20, 21) .
Models of Hypertensive Cardiac Hypertrophy with Diastolic Dysfunction
Because of the lack of adequate animal models, it has been difficult to explore the mechanisms of hypertensive diastolic dysfunction, especially isolated diastolic dysfunction at the compensated state. Hori and his colleagues have shown that Dahl salt-sensitive rats fed a high-salt diet from 7 weeks old develop hypertension followed by LV hypertrophy with diastolic dysfunction at 13 weeks and transition to overt diastolic CHF without either LV dilatation or systolic dysfunction at 19 weeks (22) . Thereafter, most rats die of CHF by 21 weeks. Accordingly, the Dahl rat model can be regarded as a model of isolated hypertensive diastolic CHF with a rapid progression and poor prognosis (22) . Using the Dahl rat model, the same laboratory has been investigating the mechanisms of transition from isolated diastolic dysfunction to decompensated CHF in hypertrophic hearts (18, 23−26) .
Aortic Constriction-Induced Cardiac Hypertrophy as a New Isolated Diastolic Dysfunction Model without CHF
Recently, we have reported that Wistar rats with a suprarenal aortic constriction (AC) are a model of cardiac hypertrophy accompanied by isolated diastolic dysfunction (27) . AC induces a rapid rise in blood pressure within 1 day, and thereafter blood pressure is elevated gradually (Fig. 1) . Meanwhile, concentric LV hypertrophy is established with a 2-fold increase in echocardiographic LV mass by day 28 (Fig. 2) . At day 28, AC rats show normal LV fractional shortening, but decreased ratio of early to late filling velocity (E/A ratio) of the transmitral Doppler flow pattern and elevated LVEDP, indicating normal systolic but abnormal diastolic function. It is noteworthy that AC rats do not show typical symptoms and signs of CHF, such as orthopnea, lung or liver congestion, or excessive body weight gain, until at least 16 weeks after the induction of hypertension.
The histological features of this model are myocyte hypertrophy and reactive myocardial fibrosis ( Fig. 2A) . Parallel to LV hypertrophy, myocyte hypertrophy develops with a 1.6-fold increase in the myocyte diameter by day 28 (Fig. 1) . Also, progressive interstitial changes are observed during LV hypertrophy: AC robustly induces fibroblast proliferation in the perivascular space at day 3. Thereafter, fibroblast proliferation and fibrotic tissue accumulation progressively extend from the perivascular space into the adjacent intermuscular interstitium. At day 28, AC rats show perivascular fibrosis associated with interstitial fibrosis surrounding the muscle fiber bundles (Fig. 2A) , which is a typical histological pattern of reactive myocardial fibrosis. And, the fibrosis area reaches to approximately 20% of the transverse area of the myocardium. There are no patchy or massive fibrotic scars replacing the areas where myocyte necrosis (replacement or reparative fibrosis) has taken place. These histological changes are similar to the myocardial remodeling seen in patients at the early stage of hypertensive heart disease (10) .
Taken together with the histological features, these findings indicate that AC rats can be considered a model of isolated hypertensive diastolic dysfunction without overt CHF, mimicking the characteristics of hypertensive patients with diastolic dysfunction at the compensated state. This new model gives us the opportunity to explore the causal relation between myocardial fibrosis and diastolic dysfunction during the development of hypertensive remodeling, particularly at the early phase, because it is possible to investigate the time course of the dramatic histological changes.
TGF-S -Mediated Reactive Fibrosis and Diastolic Dysfunction
Transforming growth factor-β (TGF-β ) is a key molecule of tissue fibrosis in physiological and pathophysiological situations ( 28 , 29 ) . In this model, myocardial TGF-β mRNA expression is upregulated after day 3 with a peak at day 7 ( Fig. 1) ( 27 ) . Thereafter, a modest elevation of TGF-β expression remains associated with marked inductions of type I and type III collagens. Moreover, immunoreactive TGF-β is detected in the interstitium, mainly at sites where fibroblasts are actively proliferating (Fig. 3C) .
Chronic administration of anti-TGF-β -neutralizing monoclonal antibody almost abolishes fibroblast proliferation, reverses type I and type III collagen expressions to nearly normal levels, and reduces the myocardial fibrosis area by approximately 80%, without affecting either blood pressure elevation or LV/myocyte hypertrophy ( 27 ) . Moreover, TGF-β function blocking reverses the decreased E / A ratio and elevated LVEDP to nearly normal levels, without changing systolic function. Thus, TGF-β -mediated myocardial fibrosis is suggested to play a pivotal role in the impairment of diastolic function in AC rats. The improvement of diastolic dysfunction induced by blocking TGF-β may be attributable mainly to a reduction in the collagen contents responsible for myocardial stiffening. Because intense perivascular fibrosis impairs oxygen diffusion to hypertrophied myocardium, it is also possible that the attenuation of perivascular fibrosis would improve relative myocardial ischemia and subsequently attenuate diastolic dysfunction.
Perivascular Inflammation and Hypertensive Remodeling
Atherosclerosis is now widely accepted as a chronic vascular inflammation disorder ( 30 ) . A pivotal role in this process is represented by circulating inflammatory cells that attach to the endothelium and migrate into the vascular lesions by interacting with adhesion molecules, such as intercellular adhesion molecule-1 (ICAM-1) and vascular adhesion molecule-1, and chemokines secreted by the activated vessel wall, such as monocyte chemoattractant protein-1 (MCP-1). Transmigration of macrophages is the earliest and most significant inflammatory event in vascular lesion formation because it induces production of inflammatory cytokines and growth factors, which in turn activate further vascular inflammation and lesion formation.
Fig. 3. Perivascular inflammatory changes in pressureoverloaded hearts. A: ICAM-1 expression (black arrowheads) is induced in the endothelium of the intramyocardial arteries with a peak at day 3 after AC (left). The serial section shows macrophage accumulation (red arrows) in the perivascular space adjacent to the arteries showing ICAM-1 expression (right). B: MCP-1 expression (brown) was induced in the entire wall of the intramyocardial arteries with a peak at day 3 after AC. C: TGF-β expression (red) is observed in the interstitium, especially in the perivascular space, which is rich in fibroblasts with a peak at day 7.
Adapted from Kuwahara et al . ( 27, 34, 35 ) .
Perivascular Inflammation in Hypertensive Hearts
Earlier studies reported that inflammatory cells, particularly macrophages, and fibroblasts showing proliferation and collagen production are found in the perivascular space of hypertrophied hearts of SHRs and experimental renovascular hypertensive rats ( 31 , 32 ) . Also, ICAM-1 expression was observed in endothelial cells of the intramyocardial arteries in these models ( 33 ) . These observations raise an attractive hypothesis that the inflammatory process plays a role in hypertensive myocardial remodeling. However, it has not been determined whether the inflammatory changes are causally linked to the fibrotic process or whether they are the result of hypertensive end-organ damage. In AC rats, an initial, rapid pressure rise triggers a series of inflammatory changes in the intramyocardial arterial wall (Fig. 1) . At days 1 − 7, ICAM-1 and MCP-1 are transiently induced in the endothelium and the media of the intramyocardial arteries, respectively (Fig. 3) . Moreover, macrophages accumulate predominantly in the perivascular space adjacent to the arteries expressing ICAM-1 and MCP-1 ( Fig. 3A and  B) . It is noteworthy that the ICAM-1 and MCP-1 inductions and macrophage infiltration are transient events, despite the fact that the blood pressure remains elevated (Fig. 1) . Also, it is of interest that macrophages and proliferating fibroblasts show similar spatial and temporal distributions. MCP-1 function blocking using a neutralizing monoclonal antibody almost abolishes macrophage infiltration and remarkably reduces TGF-β induction and fibroblast proliferation, without changing blood pressure, in AC rats (Fig. 4A ) ( 34 ) . Moreover, AC-induced perivascular and interstitial
Fig. 4. Effects of MCP-1 function blocking. A: Perivascular accumulations of macrophages (brown, top) and BrdU + (brown)/ vimentin + (red) proliferating fibroblasts (middle) at day 3 are almost abolished in rats with an aortic constriction (AC) by anti-MCP-1 neutralizing monoclonal antibody (anti-MCP-1). At day 28, AC-induced myocardial fibrosis (blue) is remarkably prevented by blocking the MCP-1 function (bottom). B: Left ventricular fractional shortening (left) and the ratio of the early to late filling velocity ( E / A ) of transmitral flow velocity (middle) are assessed on the basis of M-mode and pulse Doppler echocardiography, respectively, at day 28. Left ventricular end-diastolic pressure (LVEDP) is measured using a micromanometer-tipped catheter at day 28 (right). Sham, sham-operated rats; control IgG, non-immunized IgG. Modified from Kuwahara et al . ( 34 ).
fibrosis, but not myocyte/LV hypertrophy, are prevented by blocking MCP-1 (Fig. 4A) . Similar results are obtained when macrophage infiltration is prevented by ICAM-1 function blocking ( 35 ) . Thus, it is suggested that macrophages are recruited by the coordinated effect of MCP-1 and ICAM-1, then transmigrate to the perivascular space, and in turn activate the cascade of myocardial fibrosis. Macrophages produce not only TGF-β ( 36 ) but also profibrotic cytokines ( 37 , 38 ) . TGF-β induces a phenotypic change from fibroblasts to myofibroblasts. Activated fibroblasts and myofibroblasts then express TGF-β and other profibrotic substances, which in turn self-amplify ongoing fibrotic tissue formation ( 39 ) . Moreover, MCP-1 function blocking not only prevents myocardial fibrosis but also ameliorates diastolic dysfunction without affecting systolic function in AC rats (Fig. 4B) ( 34 ) . Accordingly, it is suggested that macrophage-mediated perivascular inflammation is a key event for triggering both the early fibrotic changes (fibroblast proliferation and TGF-β induction) and the late reactive fibrosis and diastolic dysfunction in pressure-overloaded hearts.
The AC rat model is characterized by acute hypertension. Thus, the observed phenomena may reflect an acute reaction of the hearts in response to sudden increase in blood pressure, but not a reaction to chronic hypertension. Very recently, it has been shown that increased blood pressure variability is an independent risk factor for cardiovascular events in elderly hypertensive patients ( 40 ) . Accordingly, it is possible that in hypertensive patients with exaggerated blood pressure variability, repeated, abrupt pressure elevations induce repetitive and chronic perivascular inflammation and in turn promote cardiovascular damages.
Mechanisms of Perivascular Inflammation Proinflammatory Communications around the Coronary Arterial Wall
The trigger element of ICAM-1 and MCP-1 inductions remains undetermined. AC rats did not show significant changes in plasma rennin activity ( 27 ) , serum angiotensinconverting enzyme (ACE) activity ( 41) , and the circulating levels of angiotensin II and aldosterone (unpublished data), suggesting that the systemic RAAS is not likely to play a role in cardiac remodeling. In addition, AC induces perivascular fibrosis, but not myocyte hypertrophy, in the right ventricular (RV) free-wall (34) . The increase in vascular wall tension induced by hypertension is distributed throughout the whole coronary artery trees of both LV and RV, although RV is not exposed to high pressure load. Thus, it is suggested that coronary arterial hypertension contributes to reactive myocardial fibrosis, whereas myocyte hypertrophy is attributable to LV systolic mechanical overload.
There is emerging evidence that arterial hemodynamic stress could activate the proinflammatory communications around the arterial wall (38) , which in turn could induce inflammatory mediators, including MCP-1 (Fig. 5) . First, an increase in arterial pressure is itself implicated as a strong signal for activation of MCP-1 induction in the hypertensive aortic wall (42) , suggesting that mechanical strain of the arterial wall directly upregulates MCP-1 (43) . Second, reactive oxygen species and inflammatory cytokines and growth factors, such as TGF-β, platelet-derived growth factor, and angiotensin II, are produced in the hypertensive arterial wall (44) . These factors can upregulate MCP-1 expression (37) . Taken together, these findings suggest that MCP-1 induction in pressure-overloaded hearts may occur as the result of an intricate interplay between the mechanical stimulus and the changes in proinflammatory factors derived from the neuroendocrine system, infiltrating inflammatory cells or vessel wall cells.
The Role of the Tissue Angiotensin System
AC-induced abrupt pressure rise triggers a rapid and transient activation of tissue ACE, but not serum ACE, within day 1 with a peak at day 3 ( Fig. 1) (41) . And, the time course of the ACE activation is consistent with those of ICAM-1 and MCP-1 inductions as well as macrophage infiltration. Moreover, a subdepressor dose of candesartan, an angiotensin II type I receptor (AT1) antagonist, not only suppresses the early inflammatory (MCP-1 induction and macrophage infiltration) and fibrotic (TGF-β induction and fibroblast proliferation) changes but also reduces the late reactive myocardial fibrosis, without effects on myocyte/LV hypertrophy, in AC rats (41, 45) . Angiotensin II has been shown to support inflammatory cell transmigration in an AT1 receptor-dependent manner, but not in an arterial pressure-independent manner (46, 47) . Also, angiotensin II induces MCP-1 expression in vascular smooth muscle cells (48) and macrophages (49) and upregulates TGF-β and the extracellular matrices in cardiac myocytes and fibroblasts (50) . In this model, AC-induced cardiac ACE activation is not affected by AT1 receptor blockade (41) . These results suggest that activation of the tissue angiotensin system is an event occurring upstream of the early fibroinflammatory changes and angiotensin II is one of the major paracrine/ endocrine proinflammatory factors responsible for reactive fibrosis in pressure-overloaded hearts.
There is increasing evidence suggesting that AT1 receptor and angiotensin II type 2 (AT2) receptor play reciprocal roles in the development of pressure-overload-induced cardiac remodeling (51, 52) . Thus, the roles of AT2 receptors in perivascular inflammation and reactive fibrosis should be elucidated in a future study. Also, recent studies have shown that aldosterone is a strong inducer of vascular inflammation and myocardial fibrosis (53) . It has been shown that aldosteroneinduced vascular inflammation and myocardial fibrosis are associated with high salt intake. However, we cannot deny the possibility that aldosterone, especially locally generated aldosterone, is involved in the inflammatory process in this model. Further investigations will be needed to address this issue.
Conclusions
Based on our recent studies, we suggest the novel concept that hypertensive myocardial fibrosis and diastolic dysfunction are another model of vascular inflammation. Targeting inflammatory processes, including angiotensin II, ICAM-1, and MCP-1, may be a new strategy for prevention and treatment of diastolic dysfunction in hypertensive hearts.
